News
TBDO Sessions Malcolm Bain
14/01/201612:00473.10TBDO SessionsMalcolm BainID Law PartnersSoftware protection and licensing issues…with a focus towards commercializationHost: Cappadona, SalvatoreAbstract:Software protection and licensing issues …with a focus towards commercialization: Many outcomes produced by biomedical/genomic R+D today involve software and databases. This session focuses on the legal issues of ownership, protection and exploitation of software in this area, looking at both traditional “royalty bearing” licensing and free and open source licensing, and the provision of services “in the cloud” as opposed to on premise licensing. We also look at the use and protection of databases and their licensing. Bio: Malcolm Bain is an English solicitor and...
New tools for the diagnosis of multiple sclerosis in its early stages
Scientists at the CRG and VHIR develop a new method for early diagnosis of multiple sclerosis. The finding, based on measuring a combination of proteins, makes it possible to accurately predict...
TBDO Sessions Malcolm Bain
14/01/201612:00473.10TBDO SessionsMalcolm BainID Law PartnersSoftware protection and licensing issues…with a focus towards commercializationHost: Cappadona, SalvatoreAbstract:Software protection and licensing issues …with a focus towards commercialization: Many outcomes produced by biomedical/genomic R+D today involve software and databases. This session focuses on the legal issues of ownership, protection and exploitation of software in this area, looking at both traditional “royalty bearing” licensing and free and open source licensing, and the provision of services “in the cloud” as opposed to on premise licensing. We also look at the use and protection of databases and their licensing. Bio: Malcolm Bain is an English solicitor and...
Jordi Riulas joins the Entrepreneur-In-Residence Program
Jordi will collaborate with the TBDO team at CRG, analysing emerging business opportunities in the biotech market.
Rory Johnson and members of the TBDO participated in the ‘Personalized Medicines & Biomarkers 2015’ conference in London
Rory Johnson, Ramon y Cajal fellow at the Computational Biology of RNA Processing laboratory, together with members of the TBDO team, participated in the “Personalized Medicines & Biomarkers 2015” conference, held in London UK on 2nd and 3rd December 2015. The participation to this event, organized within the frame of the Science to Business (S2B) Concept Challenge (2015 Edition) award, was a great opportunity to learn from, and network with, leaders from biotech and pharma in the field of biomarker discovery and development. We expect that this valuable experience will help Rory promoting his entrepreneurial project, focused on non-invasive RNA treatment-decision biomarkers for chronic lymphocytic leukemia.
The TBDO participated in the BioFIT event in Strasbourg
BioFIT is the leading partnering event in Europe for open innovation, technology transfer and collaborative research in the field of Life Sciences: another great opportunity for partnering, networking and promoting CRG technologies.
The TBDO will participate in the Bio-Europe 2015 in Munich
BIO-Europe is Europe's largest partnering conference serving the global biotechnology industry. The conference annually attracts leading dealmakers from biotech, pharma and finance along with the most exciting emerging companies: a great opportunity for partnering, networking and promoting CRG technologies.
CRG Proof of Concept: Commercialization Gap Fund (CGF)
Deadline: 27/11/2015
Please send your Full Proposal (max. 10 pages) under the following schemes:
- MIDI - Up to 6 months and 35 kEUR
- MAXI - Up to 12 months and 75 kEUR
Xavier Gallego joins the Entrepreneur-In-Residence Program
Health & Bio Team Dating
On 3 December 2015, Banc Sabadell, Biocat, CataloniaBio and the Bosch i Gimpera Foundation are holding Health & Bio Team Dating, an event where scientist and business professionals can talk about their projects and themselves with the aim of building a balanced team to lead successful start-up in the life sciences.